Literature DB >> 1713902

Prazosin concentration monitoring in the treatment of prostatic adenoma.

S Dutkiewicz1, M Filipek.   

Abstract

In a prospective study of 32 patients with BPH treated with Minipress (prazosin), determinations of drug plasma levels were carried out. The comparison of clinical results and serum plasma levels enabled optimalization of the dosage in long-term therapy.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1713902     DOI： 10.1007/bf02549711

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


  2 in total

1.  The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy.

Authors:  M Caine
Journal:  J Urol       Date:  1986-07       Impact factor: 7.450

Review 2.  Clinical pharmacokinetics of prazosin--1985.

Authors:  J Vincent; P A Meredith; J L Reid; H L Elliott; P C Rubin
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447
  2 in total
  2 in total

1.  Doxazosin--an alpha-1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (Part One).

Authors:  S Dutkiewicz; A Witeska
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

2.  Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia.

Authors:  S Dutkiewics
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.266
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.